165 related articles for article (PubMed ID: 29673667)
21. Preoperative CA-125 levels in 123 patients with borderline ovarian tumors: a retrospective analysis and review of the literature.
Kolwijck E; Thomas CM; Bulten J; Massuger LF
Int J Gynecol Cancer; 2009 Nov; 19(8):1335-8. PubMed ID: 20009886
[TBL] [Abstract][Full Text] [Related]
22. Current Strategy for the Treatment of Ovarian Germ Cell Tumors: Role of Extensive Surgery.
Li J; Wu X
Curr Treat Options Oncol; 2016 Aug; 17(8):44. PubMed ID: 27357180
[TBL] [Abstract][Full Text] [Related]
23. Ovarian germ cell tumours: a 17-year study in a single unit.
Panteli C; Curry J; Kiely E; Pierro A; de Coppi P; Anderson J; Sebire N; Drake D
Eur J Pediatr Surg; 2009 Apr; 19(2):96-100. PubMed ID: 19360543
[TBL] [Abstract][Full Text] [Related]
24. Malignant ovarian germ cell tumors: clinico-pathological presentation and survival outcomes.
Tangjitgamol S; Hanprasertpong J; Manusirivithaya S; Wootipoom V; Thavaramara T; Buhachat R
Acta Obstet Gynecol Scand; 2010; 89(2):182-9. PubMed ID: 19961281
[TBL] [Abstract][Full Text] [Related]
25. Prognostic importance of preoperative CA-125 in International Federation of Gynecology and Obstetrics stage I epithelial ovarian cancer: an Australian multicenter study.
Paramasivam S; Tripcony L; Crandon A; Quinn M; Hammond I; Marsden D; Proietto A; Davy M; Carter J; Nicklin J; Perrin L; Obermair A
J Clin Oncol; 2005 Sep; 23(25):5938-42. PubMed ID: 16087942
[TBL] [Abstract][Full Text] [Related]
26. A novel index for preoperative, non-invasive prediction of macro-radical primary surgery in patients with stage IIIC-IV ovarian cancer-a part of the Danish prospective pelvic mass study.
Karlsen MA; Fagö-Olsen C; Høgdall E; Schnack TH; Christensen IJ; Nedergaard L; Lundvall L; Lydolph MC; Engelholm SA; Høgdall C
Tumour Biol; 2016 Sep; 37(9):12619-12626. PubMed ID: 27440204
[TBL] [Abstract][Full Text] [Related]
27. A retrospective study of preoperative CA 125 levels in 82 patients with ovarian cancer.
Rossi AC; Di Vagno G; Cormio G; Cazzolla A; Stefanelli S; D'Elia E; Selvaggi L
Arch Gynecol Obstet; 2004 May; 269(4):263-5. PubMed ID: 14745561
[TBL] [Abstract][Full Text] [Related]
28. [Value of serum CA(125) detection for predicting recurrence and prognosis in ovarian epithelial cancer].
Wang XY; Ye J; Feng SW; Lü WG; Wan XY; Xie X
Zhonghua Fu Chan Ke Za Zhi; 2010 Nov; 45(11):813-6. PubMed ID: 21211277
[TBL] [Abstract][Full Text] [Related]
29. Outcome and risk factors for recurrence in malignant ovarian germ cell tumors: a MITO-9 retrospective study.
Mangili G; Sigismondi C; Gadducci A; Cormio G; Scollo P; Tateo S; Ferrandina G; Greggi S; Candiani M; Lorusso D
Int J Gynecol Cancer; 2011 Nov; 21(8):1414-21. PubMed ID: 21795985
[TBL] [Abstract][Full Text] [Related]
30. Preoperative CA 125 levels: an independent prognostic factor for epithelial ovarian cancer.
Cooper BC; Sood AK; Davis CS; Ritchie JM; Sorosky JI; Anderson B; Buller RE
Obstet Gynecol; 2002 Jul; 100(1):59-64. PubMed ID: 12100804
[TBL] [Abstract][Full Text] [Related]
31. Is Omentectomy Mandatory Among Early Stage (I, II) Malignant Ovarian Germ Cell Tumor Patients? A Retrospective Study of 223 Cases.
Xu W; Li Y
Int J Gynecol Cancer; 2017 Sep; 27(7):1373-1378. PubMed ID: 28520571
[TBL] [Abstract][Full Text] [Related]
32. Preoperative CA 125: an independent prognostic factor in patients with stage I epithelial ovarian cancer.
Nagele F; Petru E; Medl M; Kainz C; Graf AH; Sevelda P
Obstet Gynecol; 1995 Aug; 86(2):259-64. PubMed ID: 7617357
[TBL] [Abstract][Full Text] [Related]
33. Preoperative serum inhibin levels in patients with ovarian tumors.
El-Shalakany A; Abou-Talib Y; Shalaby HS; Sallam M
J Obstet Gynaecol Res; 2004 Apr; 30(2):155-61. PubMed ID: 15009621
[TBL] [Abstract][Full Text] [Related]
34. Elevated Preoperative CA125 or CA19-9 in Borderline Ovarian Tumors: Could It Be Suggestive of Advanced Stage or a Poor Prognosis?
Song T; Lee DH; Jung YW; Yun BS; Seong SJ; Choi CH; Lee JW; Bae DS; Kim BG
Gynecol Obstet Invest; 2018; 83(1):45-51. PubMed ID: 28571024
[TBL] [Abstract][Full Text] [Related]
35. The prognostic factor for recurrence in advanced-stage high-grade serous ovarian cancer after complete clinical remission: a nested case-control study.
Wang Q; Zheng Y; Wang P; Zhang J; Liu H; Li Q; Yin R; Bian C; Peng H; Peng Z
J Ovarian Res; 2021 Dec; 14(1):179. PubMed ID: 34930386
[TBL] [Abstract][Full Text] [Related]
36. The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma.
Chi DS; Venkatraman ES; Masson V; Hoskins WJ
Gynecol Oncol; 2000 May; 77(2):227-31. PubMed ID: 10785469
[TBL] [Abstract][Full Text] [Related]
37. Serum CA 125 Level after Neoadjuvant Chemotherapy is Predictive of Prognosis and Debulking Surgery Outcomes in Advanced Epithelial Ovarian Cancer.
Matsuhashi T; Takeshita T; Yamamoto A; Kawase R; Yamada T; Kurose K; Doi D; Konnai K; Onose R; Kato H
J Nippon Med Sch; 2017; 84(4):170-176. PubMed ID: 28978897
[TBL] [Abstract][Full Text] [Related]
38. [Correlation of preoperative serum vascular endothelial growth factor level with CA125 level in patients with epithelial ovarian cancer and its prognostic value].
Tan XJ; Lang JH; Shen K; Wang L; Wu M; Xu XY
Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):9-12. PubMed ID: 18366924
[TBL] [Abstract][Full Text] [Related]
39. Does serum CA125 have clinical value for follow-up monitoring of postoperative patients with epithelial ovarian cancer? Results of a 12-year study.
Guo N; Peng Z
J Ovarian Res; 2017 Mar; 10(1):14. PubMed ID: 28284216
[TBL] [Abstract][Full Text] [Related]
40. Primary ovarian sarcoma: analysis of prognostic variables and the role of surgical cytoreduction.
Sood AK; Sorosky JI; Gelder MS; Buller RE; Anderson B; Wilkinson EJ; Benda JA; Morgan LS
Cancer; 1998 May; 82(9):1731-7. PubMed ID: 9576296
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
